Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets

ABSTRACT: The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets

PROVIDER: PRJNA714082 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13953415.fastq.gz	Fastqsanger.gz
	SRR13953416.fastq.gz	Fastqsanger.gz
	SRR13953417.fastq.gz	Fastqsanger.gz
	SRR13953418.fastq.gz	Fastqsanger.gz
	SRR13953419.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 35

Similar Datasets

The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets

Project description:The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets

| PRJNA785165 | ENA

The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets

Project description:The resistance to transcription factor-mediated reprogramming into pluripotent stem cells is one of the distinctive features of cancer cells. Here, we dissect the profiles of the reprogramming factor binding and the subsequent transcriptional response in cancer cells to reveal the molecular mechanisms underlying this phenomenon. Using clear cell sarcomas (CCSs) as a model, we show that expression of the driver oncogene EWS/ATF1 misdirects the reprogramming factors to cancer-specific enhancer elements and thereby impairs the early transcriptional response toward pluripotency which is otherwise provoked. Consistently, sensitization to the reprogramming cue is also observed in other types of cancer when the corresponding oncogenic signals are pharmacologically inhibited. Exploiting this oncogene dependence of the transcriptional ‘stiffness’, we identify the mTOR signaling pathway downstream of EWS/ATF1, and discover inhibiting the mTOR activity substantially attenuates the propagation of CCS cells both in vitro and in vivo. Collectively, our results demonstrate that the early transcriptional response to cell fate perturbations can be a faithful readout to identify effective therapeutics in cancer cells. Moreover, the current study has implications for understanding how the cancer cell identity is robustly maintained.

2023-02-19 | GSE189931 | GEO

The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets

Project description:The resistance to transcription factor-mediated reprogramming into pluripotent stem cells is one of the distinctive features of cancer cells. Here, we dissect the profiles of the reprogramming factor binding and the subsequent transcriptional response in cancer cells to reveal the molecular mechanisms underlying this phenomenon. Using clear cell sarcomas (CCSs) as a model, we show that expression of the driver oncogene EWS/ATF1 misdirects the reprogramming factors to cancer-specific enhancer elements and thereby impairs the early transcriptional response toward pluripotency which is otherwise provoked. Consistently, sensitization to the reprogramming cue is also observed in other types of cancer when the corresponding oncogenic signals are pharmacologically inhibited. Exploiting this oncogene dependence of the transcriptional ?stiffness?, we identify the mTOR signaling pathway downstream of EWS/ATF1, and discover inhibiting the mTOR activity substantially attenuates the propagation of CCS cells both in vitro and in vivo. Collectively, our results demonstrate that the early transcriptional response to cell fate perturbations can be a faithful readout to identify effective therapeutics in cancer cells. Moreover, the current study has implications for understanding how the cancer cell identity is robustly maintained.

2023-02-19 | GSE168815 | GEO

Multi-omics unveils host perturbations by tick-borne encephalitis virus for therapeutic targets

Project description:Multi-omics unveils host perturbations by tick-borne encephalitis virus for therapeutic targets

2024-01-09 | PXD048439 |

Application of the ISM bioinformatics platform in detection of new therapeutic targets and potential therapeutic molecules

Project description:Application of EIIP / ISM bioinformatics platform in detection of new therapeutic targets and potential therapeutic molecules. Study of the molecular basis of rare human diseases

2020-12-16 | PRJEB42044 | EVA

Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets

Project description:Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets

| PRJNA483877 | ENA

Unbiased identification of CSDE1-regulated targets during oncogene-induced senescence

Project description:Unbiased identification of CSDE1-regulated targets during oncogene-induced senescence

| PRJNA671501 | ENA

Genome-wide screen unveils the synthetic lethality targets of mitomycin C

Project description:Genome-wide screen unveils the synthetic lethality targets of mitomycin C

| PRJNA548076 | ENA

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

Project description:Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

| PRJNA547577 | ENA

Multi-omics Dissection of MAPK-driven Senescence Unveils Therapeutic Vulnerabilities in KIAA1549::BRAF-fusion Pediatric Low-Grade Glioma Models

Project description:This study investigates molecular mechanisms regulating oncogene-induced senescence (OIS) and senescence-associated secretory phenotype (SASP) in pediatric low-grade gliomas (pLGGs). Using multi-omics analysis of a pilocytic astrocytoma cell line, we identified key OIS effectors and pathways affected by MAPK inhibition. We constructed a network of MAPK-OIS-SASP interdependencies, revealing potential therapeutic targets. Several compounds targeting signaling nodes were identified and validated, suggesting new treatment strategies for pLGGs.

2025-06-30 | PXD060126 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data